+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Asia Pacific Pharmaceutical Contract Manufacturing Market 2020-2030 by Category, Product (API, FDF), Phase (Clinical, Commercial), Type (Sterile, Non-Sterile), Therapeutic Application, and Country: Trend Forecast and Growth Opportunity

  • ID: 5182598
  • Report
  • October 2020
  • Region: Asia Pacific
  • 115 pages
  • GMD Research

Order now to receive an updated version of this report covering the impact of COVID-19.

Enquire Now

FEATURED COMPANIES

  • Aenova Group
  • Boehringer Ingelheim
  • Catalent Inc.
  • Famar S.A.
  • Hospira, Inc.
  • Lonza Group
Asia Pacific pharmaceutical contract manufacturing market will grow by 7.6% annually with a total addressable market cap of $489.1 billion over 2020-2030 owing to the rising need for medicines amid COVID-19 pandemic and increasing dependence on contract manufacturing organizations due to improved efficiency and productivity.

Highlighted with 38 tables and 53 figures, this 116-page report “Asia Pacific Pharmaceutical Contract Manufacturing Market 2020-2030 by Category, Product (API, FDF), Phase (Clinical, Commercial), Type (Sterile, Non-Sterile), Therapeutic Application, and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Asia Pacific pharmaceutical contract manufacturing market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year.

In-depth qualitative analyses include identification and investigation of the following aspects:
  • Market Structure
  • Growth Drivers
  • Restraints and Challenges
  • Emerging Product Trends & Market Opportunities
  • Porter’s Five Forces
The trend and outlook of Asia Pacific market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Asia Pacific pharmaceutical contract manufacturing market in every aspect of the classification from perspectives of Category, Product, Phase, Type, Therapeutic Application, and Country.

Based on Category, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
  • Pharmaceutical Industry
  • Biopharmaceutical Industry
Based on Product, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

Active Pharmaceutical Ingredients (API)
  • Branded API Manufacturing
  • Generic API Manufacturing
Finished Dosage Formulations (FDF)
  • Solid Dosage
  • Oral Liquids
  • Parenteral/Injectables
  • Other FDFs
Secondary Packaging

Based on Phase, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
  • Clinical Manufacturing
  • Commercial Manufacturing
Based on Type, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
  • Sterile Products
  • Non-Sterile Products
Based on Therapeutic Application, the Asia Pacific market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
  • Infectious Diseases
  • Oncology
  • Metabolic Disorders
  • Cardiovascular Disorders
  • Central Nervous System
  • Pulmonary Disorders
  • Gastrointestinal Disorders
  • Other Therapeutic Applications
Geographically, the following national/local markets are fully investigated:
  • Japan
  • China
  • South Korea
  • Australia
  • India
  • Rest of APAC (further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka)
For each country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of key national markets by Product, Phase, and Therapeutic Application over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.

Specifically, potential risks associated with investing in Asia Pacific pharmaceutical contract manufacturing market are assayed quantitatively and qualitatively through a Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.

Key Players (this may not be a complete list and extra companies can be added upon request):
  • Aenova Group
  • Baxter BioPharma Solutions
  • Boehringer Ingelheim
  • Catalent Inc.
  • Famar S.A.
  • Hospira, Inc.
  • Jubilant Life Sciences Ltd.
  • Lonza Group
  • Patheon Inc.
  • Pfizer CentreSource
  • Recipharm AB
  • Vetter Pharma International GmbH
(Please Note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Aenova Group
  • Boehringer Ingelheim
  • Catalent Inc.
  • Famar S.A.
  • Hospira, Inc.
  • Lonza Group
1 Introduction
1.1 Industry Definition and Research Scope
1.1.1 Industry Definition
1.1.2 Research Scope
1.2 Research Methodology
1.2.1 Overview of Market Research Methodology
1.2.2 Market Assumption
1.2.3 Secondary Data
1.2.4 Primary Data
1.2.5 Data Filtration and Model Design
1.2.6 Market Size/Share Estimation
1.2.7 Research Limitations
1.3 Executive Summary

2 Market Overview and Dynamics
2.1 Market Size and Forecast
2.1.1 Impact of COVID-19 on World Economy
2.1.2 Impact of COVID-19 on the Market
2.2 Major Growth Drivers
2.3 Market Restraints and Challenges
2.4 Emerging Opportunities and Market Trends
2.5 Porter’s Five Forces Analysis

3 Segmentation of Asia Pacific Market by Category
3.1 Market Overview by Category
3.2 Pharmaceutical Industry
3.3 Biopharmaceutical Industry

4 Segmentation of Asia Pacific Market by Product
4.1 Market Overview by Product
4.2 Active Pharmaceutical Ingredients (API)
4.2.1 Branded API Manufacturing
4.2.2 Generic API Manufacturing
4.3 Finished Dosage Formulations (FDF)
4.3.1 Solid Dosage
4.3.2 Oral Liquids
4.3.3 Parenteral/Injectables
4.3.4 Other FDFs
4.4 Secondary Packaging

5 Segmentation of Asia Pacific Market by Phase
5.1 Market Overview by Phase
5.2 Clinical Manufacturing
5.3 Commercial Manufacturing

6 Segmentation of Asia Pacific Market by Type
6.1 Market Overview by Type
6.2 Sterile Products
6.3 Non-Sterile Products

7 Segmentation of Asia Pacific Market by Therapeutic Application
7.1 Market Overview by Therapeutic Application
7.2 Infectious Diseases
7.3 Oncology
7.4 Metabolic Disorders
7.5 Cardiovascular Disorders
7.6 Central Nervous System
7.7 Pulmonary Disorders
7.8 Gastrointestinal Disorders
7.9 Other Therapeutic Applications

8 Asia-Pacific Market 2019-2030 by Country
8.1 Overview of Asia-Pacific Market
8.2 Japan
8.3 China
8.4 Australia
8.5 India
8.6 South Korea
8.7 Rest of APAC Region

9 Competitive Landscape
9.1 Overview of Key Vendors
9.2 New Product Launch, Partnership, Investment, and M&A
9.3 Company Profiles
  • Aenova Group
  • Baxter BioPharma Solutions
  • Boehringer Ingelheim
  • Catalent Inc.
  • Famar S.A.
  • Hospira, Inc.
  • Jubilant Life Sciences Ltd.
  • Lonza Group
  • Patheon Inc.
  • Pfizer CentreSource
  • Recipharm AB
  • Vetter Pharma International GmbH
10 Investing in Asia Pacific Market: Risk Assessment and Management
10.1 Risk Evaluation of Asia Pacific Market
10.2 Critical Success Factors (CSFs)

List of Tables
Table 1. Snapshot of Asia Pacific Pharmaceutical Contract Manufacturing Market, 2019-2030
Table 2. Growth Rate of World Real GDP, 2017-2021
Table 3. Main Product Trends and Market Opportunities in Asia Pacific Pharmaceutical Contract Manufacturing Market
Table 4. Asia Pacific Pharmaceutical Contract Manufacturing Market by Category, 2019-2030, $ bn
Table 5. Asia Pacific Pharmaceutical Contract Manufacturing Market by Product, 2019-2030, $ bn
Table 6. Asia Pacific Pharmaceutical Contract Manufacturing Market: Active Pharmaceutical Ingredients (API) by Type, 2019-2030, $ bn
Table 7. Asia Pacific Pharmaceutical Contract Manufacturing Market: Finished Dosage Formulations (FDF) by Type, 2019-2030, $ bn
Table 8. Asia Pacific Pharmaceutical Contract Manufacturing Market by Phase, 2019-2030, $ bn
Table 9. Asia Pacific Pharmaceutical Contract Manufacturing Market by Type, 2019-2030, $ bn
Table 10. Asia Pacific Pharmaceutical Contract Manufacturing Market by Therapeutic Application, 2019-2030, $ bn
Table 11. APAC Pharmaceutical Contract Manufacturing Market by Country, 2019-2030, $ bn
Table 12. Japan Pharmaceutical Contract Manufacturing Market by Product, 2019-2030, $ bn
Table 13. Japan Pharmaceutical Contract Manufacturing Market by Phase, 2019-2030, $ bn
Table 14. Japan Pharmaceutical Contract Manufacturing Market by Therapeutic Application, 2019-2030, $ bn
Table 15. China Pharmaceutical Contract Manufacturing Market by Product, 2019-2030, $ bn
Table 16. China Pharmaceutical Contract Manufacturing Market by Phase, 2019-2030, $ bn
Table 17. China Pharmaceutical Contract Manufacturing Market by Therapeutic Application, 2019-2030, $ bn
Table 18. Australia Pharmaceutical Contract Manufacturing Market by Product, 2019-2030, $ bn
Table 19. Australia Pharmaceutical Contract Manufacturing Market by Phase, 2019-2030, $ bn
Table 20. Australia Pharmaceutical Contract Manufacturing Market by Therapeutic Application, 2019-2030, $ bn
Table 21. India Pharmaceutical Contract Manufacturing Market by Product, 2019-2030, $ bn
Table 22. India Pharmaceutical Contract Manufacturing Market by Phase, 2019-2030, $ bn
Table 23. India Pharmaceutical Contract Manufacturing Market by Therapeutic Application, 2019-2030, $ bn
Table 24. South Korea Pharmaceutical Contract Manufacturing Market by Product, 2019-2030, $ bn
Table 25. South Korea Pharmaceutical Contract Manufacturing Market by Phase, 2019-2030, $ bn
Table 26. South Korea Pharmaceutical Contract Manufacturing Market by Therapeutic Application, 2019-2030, $ bn
Table 27. Pharmaceutical Contract Manufacturing Market in Rest of APAC by Country, 2019-2030, $ bn
Table 28. Aenova Group: Company Snapshot
Table 29. Aenova Group: Business Segmentation
Table 30. Aenova Group: Product Portfolio
Table 31. Aenova Group: Revenue, 2016-2018, $ bn
Table 32. Aenova Group: Recent Developments
Table 33. Risk Evaluation for Investing in Asia Pacific Market, 2019-2030
Table 34. Critical Success Factors and Key Takeaways

List of Figures
Figure 1. Research Method Flow Chart
Figure 2. Breakdown of Primary Research
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation
Figure 4. Asia Pacific Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030
Figure 5. Asia Pacific Pharmaceutical Contract Manufacturing Market, 2019-2030, $ bn
Figure 6. Impact of COVID-19 on Business
Figure 7. Primary Drivers and Impact Factors of Asia Pacific Pharmaceutical Contract Manufacturing Market
Figure 8. Primary Restraints and Impact Factors of Asia Pacific Pharmaceutical Contract Manufacturing Market
Figure 9. Investment Opportunity Analysis
Figure 10. Porter’s Five Forces Analysis of Asia Pacific Pharmaceutical Contract Manufacturing Market
Figure 11. Breakdown of Asia Pacific Pharmaceutical Contract Manufacturing Market by Category, 2019-2030, % of Revenue
Figure 12. Asia Pacific Addressable Market Cap in 2020-2030 by Category, Value ($ bn) and Share (%)
Figure 13. Asia Pacific Pharmaceutical Contract Manufacturing Market: Pharmaceutical Industry, 2019-2030, $ bn
Figure 14. Asia Pacific Pharmaceutical Contract Manufacturing Market: Biopharmaceutical Industry, 2019-2030, $ bn
Figure 15. Breakdown of Asia Pacific Pharmaceutical Contract Manufacturing Market by Product, 2019-2030, % of Sales Revenue
Figure 16. Asia Pacific Addressable Market Cap in 2020-2030 by Product, Value ($ bn) and Share (%)
Figure 17. Asia Pacific Pharmaceutical Contract Manufacturing Market: Active Pharmaceutical Ingredients (API), 2019-2030, $ bn
Figure 18. Asia Pacific Pharmaceutical Contract Manufacturing Market: Branded API Manufacturing, 2019-2030, $ bn
Figure 19. Asia Pacific Pharmaceutical Contract Manufacturing Market: Generic API Manufacturing, 2019-2030, $ bn
Figure 20. Asia Pacific Pharmaceutical Contract Manufacturing Market: Finished Dosage Formulations (FDF), 2019-2030, $ bn
Figure 21. Asia Pacific Pharmaceutical Contract Manufacturing Market: Solid Dosage, 2019-2030, $ bn
Figure 22. Asia Pacific Pharmaceutical Contract Manufacturing Market: Oral Liquids, 2019-2030, $ bn
Figure 23. Asia Pacific Pharmaceutical Contract Manufacturing Market: Parenteral/Injectables, 2019-2030, $ bn
Figure 24. Asia Pacific Pharmaceutical Contract Manufacturing Market: Other FDFs, 2019-2030, $ bn
Figure 25. Asia Pacific Pharmaceutical Contract Manufacturing Market: Secondary Packaging, 2019-2030, $ bn
Figure 26. Breakdown of Asia Pacific Pharmaceutical Contract Manufacturing Market by Phase, 2019-2030, % of Sales Revenue
Figure 27. Asia Pacific Addressable Market Cap in 2020-2030 by Phase, Value ($ bn) and Share (%)
Figure 28. Asia Pacific Pharmaceutical Contract Manufacturing Market: Clinical Manufacturing, 2019-2030, $ bn
Figure 29. Asia Pacific Pharmaceutical Contract Manufacturing Market: Commercial Manufacturing, 2019-2030, $ bn
Figure 30. Breakdown of Asia Pacific Pharmaceutical Contract Manufacturing Market by Type, 2019-2030, % of Revenue
Figure 31. Asia Pacific Addressable Market Cap in 2020-2030 by Type, Value ($ bn) and Share (%)
Figure 32. Asia Pacific Pharmaceutical Contract Manufacturing Market: Sterile Products, 2019-2030, $ bn
Figure 33. Asia Pacific Pharmaceutical Contract Manufacturing Market: Non-Sterile Products, 2019-2030, $ bn
Figure 34. Breakdown of Asia Pacific Pharmaceutical Contract Manufacturing Market by Therapeutic Application, 2019-2030, % of Revenue
Figure 35. Asia Pacific Addressable Market Cap in 2020-2030 by Therapeutic Application, Value ($ bn) and Share (%)
Figure 36. Asia Pacific Pharmaceutical Contract Manufacturing Market: Infectious Diseases, 2019-2030, $ bn
Figure 37. Asia Pacific Pharmaceutical Contract Manufacturing Market: Oncology, 2019-2030, $ bn
Figure 38. Asia Pacific Pharmaceutical Contract Manufacturing Market: Metabolic Disorders, 2019-2030, $ bn
Figure 39. Asia Pacific Pharmaceutical Contract Manufacturing Market: Cardiovascular Disorders, 2019-2030, $ bn
Figure 40. Asia Pacific Pharmaceutical Contract Manufacturing Market: Central Nervous System, 2019-2030, $ bn
Figure 41. Asia Pacific Pharmaceutical Contract Manufacturing Market: Pulmonary Disorders, 2019-2030, $ bn
Figure 42. Asia Pacific Pharmaceutical Contract Manufacturing Market: Gastrointestinal Disorders, 2019-2030, $ bn
Figure 43. Asia Pacific Pharmaceutical Contract Manufacturing Market: Other Therapeutic Applications, 2019-2030, $ bn
Figure 44. Breakdown of APAC Pharmaceutical Contract Manufacturing Market by Country, 2019 and 2030, % of Revenue
Figure 45. Contribution to APAC 2020-2030 Cumulative Revenue by Country, Value ($ bn) and Share (%)
Figure 46. Pharmaceutical Contract Manufacturing Market in Japan, 2019-2030, $ bn
Figure 47. Pharmaceutical Contract Manufacturing Market in China, 2019-2030, $ bn
Figure 48. Pharmaceutical Contract Manufacturing Market in Australia, 2019-2030, $ bn
Figure 49. Pharmaceutical Contract Manufacturing Market in India, 2019-2030, $ bn
Figure 50. Pharmaceutical Contract Manufacturing Market in South Korea, 2019-2030, $ bn
Figure 51. Pharmaceutical Contract Manufacturing Market in Rest of APAC, 2019-2030, $ bn
Figure 52. Growth Stage of Asia Pacific Pharmaceutical Contract Manufacturing Industry over the Forecast Period
Note: Product cover images may vary from those shown
  • Aenova Group
  • Baxter BioPharma Solutions
  • Boehringer Ingelheim
  • Catalent Inc.
  • Famar S.A.
  • Hospira, Inc.
  • Jubilant Life Sciences Ltd.
  • Lonza Group
  • Patheon Inc.
  • Pfizer CentreSource
  • Recipharm AB
  • Vetter Pharma International GmbH
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll